Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14071751
Abstract: Simple Summary This analysis assesses the efficacy of brigatinib, a next-generation ALK inhibitor in ALK+ advanced non-small cell lung cancer (aNSCLC) included in the brigatinib French Early-Access Program (1 August 2016–21 January 2019), with a… read more here.
Keywords: brigatinib; post brigatinib; months median; efficacy ... See more keywords